Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

MLA

Lindsey E. Roeker, et al. “Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia.” Blood, vol. 140, Nov. 2022, pp. 4156–58. EBSCOhost, https://doi.org/10.1182/blood-2022-167213.

APA

Lindsey E. Roeker, Maral DerSarkissian, Kellie J. Ryan, Yan Chen, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, & Anthony R. Mato. (2022). Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia. Blood, 140, 4156–4158. https://doi.org/10.1182/blood-2022-167213

Chicago

Lindsey E. Roeker, Maral DerSarkissian, Kellie J. Ryan, Yan Chen, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, and Anthony R. Mato. 2022. “Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia.” Blood 140 (November): 4156–58. doi:10.1182/blood-2022-167213.